Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
OwnerDaniel Mark COREY, Nathan KIPNISS +1inventors
InventorsDaniel Mark COREY, Nathan KIPNISS, Geoff O'DONOGHUE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to combination therapy compositions and methods comprising chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and PARP inhibitors.
Claims31
A method for treating a cancer, wherein the cancer is breast cancer, ovarian cancer, colorectal cancer, fallopian cancer, peritoneal cancer, prostate cancer, lung cancer, or melanoma, in a subject in need thereof, the method comprising administering to the subject an effective amount of an engineered T cell comprising:
- a chimeric engulfment receptor comprising a single chain chimeric protein, the single chain chimeric protein comprising:
- (a) an extracellular domain comprising a binding domain comprising:
- (i) a Tim4 IgV domain;
- and
- (ii) a Tim4 mucin domain;
- (b) an intracellular signaling domain, wherein the intracellular signaling domain comprises a primary intracellular signaling domain, wherein the primary signaling domain comprises a CD28 signaling domain or a TLR2 signaling domain and a secondary intracellular signaling domain, wherein the secondary signaling domain comprises a CD3ζ signaling domain or a DAP12 signaling domain;
- and
- (c) a transmembrane domain positioned between and connecting the extracellular domain and the intracellular signaling domain;
- and
- a Poly (ADP-ribose) polymerase (PARP) inhibitor).
(canceled)
-19. (canceled)
(canceled)
(canceled)
-31. (canceled)
-35. (canceled)
-49. (canceled)
-64. (canceled)
-75. (canceled)
-79. (canceled)
-85. (canceled)
Dependencies are inferred from the claim text.